A Study of a Melatonin Receptor Agonist to Prevent Migraine
Status:
Terminated
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see if ramelteon will reduce the number of migraine headaches
over a 12 week period. The safety and tolerability of ramelteon will also be evaluated.
Ramelteon has been approved by the U.S. Food and Drug Administration (FDA) for insomnia
(trouble sleeping); however; ramelteon has not been approved for the prevention of migraines.